Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
JNJ 164.99 -2.37(-1.42%)
Will JNJ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Is Invesco S&P 500 Quality ETF (SPHQ) a Strong ETF Right Now?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
Other News for JNJ
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Johnson & Johnson Sweetens Talc Settlement Deal by $1.1B
Johnson & Johnson (JNJ) Wells Fargo 2024 Healthcare Conference (Transcript)
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
JNJ October 25th Options Begin Trading